What is the price of dabrafenib and trametinib in China? Price comparison and patient selection

Dabrafenib and trametinib (Trametinib) are two targeted drugs commonly used to treat BRAF mutation-positive malignant melanoma and some other cancers. They are often used in combination to work synergistically to improve efficacy. Both are targeted drugs, targeting BRAF and MEK1/2 respectively, and play an important role in the treatment of related types of tumors. However, the market prices of these two drugs are quite different, and it is crucial for patients to understand the price comparison and choice between these two drugs, especially in terms of medical insurance coverage and financial burden.

Domestic price and selection of trametinib

Trametinib (Trametinib), as a MEK1/2 inhibitor, has been officially launched in China and has been included in the medical insurance catalog. Patients can enjoy certain medical insurance reimbursement support when purchasing. Trametinib has different specifications in the Chinese market, including 0.5mg 30 tablets and 2mg 30 tablets, with obvious price differences. According to the latest market information, the latest selling price of 0.5mg30 tablets is about three to four thousand yuan, while the latest selling price of 2mg30 tablets is between more than nine thousand yuan and more than ten thousand yuan. The specific price depends on the hospital where the patient is located and the local medical insurance policy.

In addition to domestic original drugs, there are also trametinib products from different sources on the foreign market. For example, the original research version 2mg*30 tablets produced in Türkiye is priced at about 7,000 to 8,000 yuan, which is slightly lower than the Chinese original research version. However, Laos has approved a generic version of trametinib, and the price of the drug is much cheaper, with the latest selling price being about more than 1,000 yuan. This price is relatively low, but it can still ensure the therapeutic effect of the drug because its drug ingredients are highly consistent with the original drug. Therefore, when patients purchase trametinib, they can choose a suitable version according to their own financial situation.

Domestic price and selection of dabrafenib

Dabrafenib (Dabrafenib), as a BRAF inhibitor, has a significant effect in the treatment of BRAF mutation-positive tumors. Dabrafenib has also been launched in China and has been included in medical insurance. The latest domestic price of 75mg*120 tablets is between more than 9,000 to more than 10,000 yuan. The specific medical insurance reimbursement price needs to be confirmed according to the hospital where the patient is located and the medical insurance policy. Since dabrafenib plays a key role in the treatment of BRAF mutation-positive malignant tumors, especially when combined with trametinib, its effect is more significant. Therefore, for patients, despite its higher price, with the support of medical insurance, the burden of treatment has been reduced.

Similarly, dabrafenib is also available as original drug and generic drug in foreign markets. For example, the price of Turkey's original research version 75mg*120 capsules is about 11,000 yuan, which is slightly higher than that of China's original research version. Like trametinib, the Lao Ministry of Health has also approved the marketing of a generic version of dabrafenib, and its pharmaceutical ingredients are highly similar to the original drug. The latest price is about 2,000 yuan. For some patients, choosing Laos generic drugs can undoubtedly greatly reduce the burden of treatment, and the therapeutic effects are almost the same as those of the original drugs.

Comprehensive comparison and patient selection

To sum up, the prices of the original drugs of dabrafenib and trametinib are relatively high, especially when purchased domestically. Due to the different reimbursement ratios of medical insurance, the actual cost of the patients will still be greatly affected. For some patients with more difficult financial circumstances, choosing overseas generic drugs may be a feasible option. The price of generic drugs in Laos has significant advantages over original drugs, and the drug ingredients are highly consistent with the original drugs, so patients can rest assured when using them.

For patients, which drug or version of the drug to choose mainly depends on the following factors: First, the patient's economic status. If medical insurance reimbursement is not high, generic drugs may become a more economical choice; second, the drug supply situation of the hospital where the patient is located, drug pricing and medical insurance policies of different hospitals may be different; third, the patient's dependence on drugs and treatment needs. If the patient requires higher treatment effects, he may be inclined to choose the original drug.

In general, dabrafenib and trametinib are the key drugs in the combination treatment regimen. Although their original drugs are more expensive, these two drugs are still crucial treatments for many patients with BRAF mutation-positive tumors. Patients can choose a suitable drug source based on their own financial situation, medical insurance reimbursement status, and doctor's recommendations. On the premise of ensuring drug quality and therapeutic effect, choosing cost-effective generic drugs is also an option worth considering.

Reference materials:https://go.drugbank.com/drugs/DB08912